These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Management of metastatic prostate cancer: the crucial role of geriatric assessment. Droz JP; Chaladaj A BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689 [TBL] [Abstract][Full Text] [Related]
30. Prostate cancer in the late 1990s: hormone refractory disease options. Moul JW; Lipo DR Urol Nurs; 1999 Jun; 19(2):125-31; quiz 132-3. PubMed ID: 10633763 [TBL] [Abstract][Full Text] [Related]
31. [Therapeutic options for hormone-refractory prostate cancer]. Miller K; Börgermann C; Thüroff J; Albers P; Wirth M Urologe A; 2006 May; 45(5):580, 582-5. PubMed ID: 16710677 [TBL] [Abstract][Full Text] [Related]
32. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142 [TBL] [Abstract][Full Text] [Related]
33. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Silvestris N; Leone B; Numico G; Lorusso V; De Lena M Oncology; 2005; 69(4):273-82. PubMed ID: 16282706 [TBL] [Abstract][Full Text] [Related]
34. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Petrylak DP Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271 [TBL] [Abstract][Full Text] [Related]
35. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy. Pienta KJ; Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047 [TBL] [Abstract][Full Text] [Related]
36. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO; Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992 [TBL] [Abstract][Full Text] [Related]
37. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298 [TBL] [Abstract][Full Text] [Related]